GlassScriptPhysician profile
Robbi L Franklin
NPI 1619171279
$13,665.51
in general payments reported to CMS, 2019-2025
26 companies · $501 in 2025
The $501 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,035 · 2020: $8,499 · 2021: $1,239 · 2022: $534 · 2023: $1,371 · 2024: $488 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,359.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $8,165.16 | 2020 | |
| Medtronic, INC. | $2,024.11 | 2021-2024 | Pipeline, Solitaire X, Axium Primetm |
| Gt Medical Technologies, INC | $639.34 | 2020-2023 | Gammatile |
| Novocure INC. | $547.27 | 2019-2025 | Optune Gio, Optune |
| Medtronic USA, INC. | $482.86 | 2019-2020 | |
| Stryker Corporation | $386.76 | 2019-2025 | Surpass Evolve, Target, Universal Neuro 3 |
| Abbott Laboratories | $223.09 | 2021-2024 | Proclaim |
| Astrazeneca Pharmaceuticals LP | $201.24 | 2021-2023 | Andexxa |
| Imperative Care, INC | $157.45 | 2024-2025 | Zoom Reperfusion Catheter, Zoom Rdl Radial Access System, 103cm, Zoom 88-T Large Distal Platform |
| Monteris Medical Corporation | $141.93 | 2022-2025 | Neuroblate |
| Arbor Pharmaceuticals, INC. | $113.11 | 2019-2021 | |
| Irras USA, INC. | $111.39 | 2019 | |
| Integra Lifesciences Corporation | $96.39 | 2019-2023 | Cusa Clarity, Codman Hakim, Duraseal Exact Spinal Sealant System |
| Ge Healthcare | $76.22 | 2019 | |
| Mizuho America, INC. | $67.61 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kls-Martin L.P. | $45.71 | 2021 | |
| Alexion Pharmaceuticals, INC. | $39.51 | 2021 | |
| Azurity Pharmaceuticals, INC. | $36.21 | 2023 | Gliadel, Triptodur |
| Depuy Synthes Sales INC. | $19.38 | 2024 | Embotrap |
| Kaleo, INC. | $18.97 | 2024 | Auvi-Q |
| Portola Pharmaceuticals, LLC | $18.46 | 2019 | |
| Sanara Medtech INC. | $14.76 | 2020 | |
| Misonix INC | $14.61 | 2020 | |
| Orthofix Medical, INC. | $12.01 | 2019 | |
| Aesculap, INC. | $11.96 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,999,010.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robbi Franklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.